GlaxoSmithKline
GSK: 1,471.06 0.00 (0.00%)
| Bid Price | 0.00 | High Price | 0.00 |
|---|---|---|---|
| Ask Price | 0.00 | Low Price | 0.00 |
| Open Price | 0.00 | Spread | 0.00% |
| Prev Close | 1,471.00 | Volume | 0.00 |
GlaxoSmithKline Share Price Chart
Intraday
Historic – 1 year
GlaxoSmithKline Share Price Information
| Name | GlaxoSmithKline | Epic | GSK |
|---|---|---|---|
| Sector | Pharmaceuticals & Biotechnology | ISIN | GB0009252882 |
| Activites | GlaxoSmithKline (GSK) is a world leading research-based pharmaceutical company with a powerful combination of skills and resources that provides a platform for delivering strong growth in today’s rapidly changing healthcare environment. Headquartered in the UK and with operations based in the US, the new company is one of the industry leaders, with an estimated seven per cent of the world’s pharmaceutical market. GSK also has leadership in four major therapeutic areas – anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic. In addition, it is a leader in the important area of vaccines and has a growing portfolio of oncology products. The company also has a Consumer Healthcare portfolio comprising over-the-counter (OTC) medicines, oral care products and nutritional healthcare drinks, all of which are among the market leaders. GSK has over 100,000 employees worldwide. Of these, over 40,000 are in sales and marketing, the largest sales force in the industry. Around 35,000 employees work at 82 manufacturing sites in 37 countries and over 15,000 are in R&D.; GSK R&D; is based at 24 sites in 11 countries. The company has a leading position in genomics/genetics and new drug discovery technologies. The GSK R&D; budget is about £2.8bn/$5bn. | Security Type | Equity |
Key numbers
| Latest Share Price (p) | 0.00 | Net Gearing (%) | 72.48 |
|---|---|---|---|
| Market Cap (£m) | 71,192.94 | Gross Gearing (%) | 83.39 |
| Shares in issue (m) | 4,876.23 | Debt Ratio | 77.82 |
| P/E Ratio | 8.38 | Debt-to-Equity Ratio | 0.70 |
| Divs per share (p) | 80.00 | Assets / Equity Ratio | 6.02 |
| Dividend Yield (%) | 5.48 | Price to book value | 8.02 |
| Dividend Cover | 1.24 | SROCE (%) | 26.30 |
| Earning per share (p) | 174.30 | EPS Growth (%) | 204.19 |
| 52-week high / low (p) | 1,803.30 / 1,277.50 | DPS Growth (%) | 0.00 |
GlaxoSmithKline Broker Views
| Date | Broker | Rec. | Price | Old target price | New target price | Notes |
|---|---|---|---|---|---|---|
| 06 Dec | JP Morgan Cazenove | Neutral | 1,471.06 | 1800.00 | 1800.00 | Retains |
| 05 Dec | Beaufort Securities | Buy | 1,471.06 | Retains | ||
| 01 Dec | Goldman Sachs | Buy | 1,471.06 | Reiterates | ||
| 17 Nov | Shore Capital | Hold | 1,471.06 | Retains | ||
| 11 Nov | Jefferies International | Buy | 1,471.06 | 1950.00 | 1850.00 | Reiterates |
GlaxoSmithKline Director Deals
| Date | Director | Type | Volume / Price | Trade Value |
|---|---|---|---|---|
| 02 Dec 2016 | Simon Dingemans | Exercise | 216 @ 1247.00p | £2,693.52 |
| 27 Oct 2016 | Andrew Witty | Sell | 10000 @ 1636.50p | £163,650.00 |
| 26 Oct 2016 | Sir Philip Hampton | Buy | 2663 @ 1643.00p | £43,753.09 |
| 18 Oct 2016 | Simon Dingemans | Dividend Reinvestment | 7111 @ 1700.00p | £120,887.00 |
| 18 Oct 2016 | Emma Walmsley | Dividend Reinvestment | 5770 @ 1700.00p | £98,090.00 |
| 18 Oct 2016 | Andrew Witty | Dividend Reinvestment | 20092 @ 1700.00p | £341,564.00 |
| 18 Oct 2016 | Emma Walmsley | Dividend Reinvestment | 1224 @ 1700.00p | £20,808.00 |
| 18 Oct 2016 | Simon Dingemans | Dividend Reinvestment | 1698 @ 1700.00p | £28,866.00 |
| 14 Oct 2016 | Andrew Witty | Dividend Reinvestment | 229 @ 1698.45p | £3,889.45 |
| 14 Oct 2016 | Andrew Witty | Dividend Reinvestment | 87779 @ 1703.88p | £1,495,648.83 |
| 12 Sep 2016 | Simon Dingemans | Buy | 8 @ 1615.50p | £129.24 |
| 12 Sep 2016 | Andrew Witty | Buy | 8 @ 1615.50p | £129.24 |
| 10 Aug 2016 | Simon Dingemans | Buy | 8 @ 1679.75p | £134.38 |
| 10 Aug 2016 | Andrew Witty | Buy | 8 @ 1679.75p | £134.38 |
| 19 Jul 2016 | Andrew Witty | Dividend Reinvestment | 17476 @ 1628.50p | £284,596.66 |
| 28 Jul 2016 | Andrew Witty | Sell | 10000 @ 1693.00p | £169,300.00 |
| 18 Jul 2016 | Simon Dingemans | Dividend Reinvestment | 112161 @ 1667.81p | £1,870,632.37 |
| 18 Jul 2016 | Andrew Witty | Dividend Reinvestment | 58 @ 1658.75p | £962.08 |
| 18 Jul 2016 | Andrew Witty | Dividend Reinvestment | 55 @ 1658.75p | £912.31 |
| 18 Jul 2016 | Andrew Witty | Dividend Reinvestment | 56 @ 1634.00p | £915.04 |
| 18 Jul 2016 | Andrew Witty | Dividend Reinvestment | 1926 @ 1658.75p | £31,947.53 |
| 18 Jul 2016 | Andrew Witty | Dividend Reinvestment | 46 @ 1634.00p | £751.64 |
| 18 Jul 2016 | Andrew Witty | Dividend Reinvestment | 101 @ 1634.00p | £1,650.34 |
| 18 Jul 2016 | Moncef Slaoui | Dividend Reinvestment | 1924 @ 1667.81p | £32,088.66 |
| 18 Jul 2016 | Andrew Witty | Dividend Reinvestment | 25592 @ 1667.81p | £426,825.94 |
| 18 Jul 2016 | Simon Dingemans | Dividend Reinvestment | 14 @ 1663.73p | £232.92 |
| 18 Jul 2016 | Andrew Witty | Dividend Reinvestment | 38 @ 1663.73p | £632.22 |
| 18 Jul 2016 | Andrew Witty | Dividend Reinvestment | 6989 @ 1658.75p | £115,930.04 |
| 12 Jul 2016 | Simon Dingemans | Buy | 7 @ 1671.27p | £116.99 |
| 12 Jul 2016 | Andrew Witty | Buy | 7 @ 1671.27p | £116.99 |
| 01 Jul 2016 | Urs Rohner | In Lieu of Fees/Salary | 541 @ 1559.00p | £8,434.19 |
| 01 Jul 2016 | Stacey Cartwright | In Lieu of Fees/Salary | 461 @ 1559.00p | £7,186.99 |
| 01 Jul 2016 | Manvinder Banga | In Lieu of Fees/Salary | 2140 @ 1559.00p | £33,362.60 |
| 01 Jul 2016 | Roy Anderson | In Lieu of Fees/Salary | 581 @ 1559.00p | £9,057.79 |
| 01 Jul 2016 | Sir Philip Hampton | In Lieu of Fees/Salary | 2806 @ 1559.00p | £43,745.54 |
GlaxoSmithKline Company News
Director Deals – GlaxoSmithKline PLC (GSK)
Simon Dingemans, Financial Director, exercised 216 shares in the company on the 1st December 2016 at a price of 1247.00p. The Director now holds 469,226 shares.
Story provided by StockMarketWire.com
Director deals data provided by www.directorsholdings.com
GSK files closed triple therapy for COPD in EU
GlaxoSmithKline and Innoviva have announced the filing by GSK of a regulatory submission with the European Medicines Agency for once-daily, closed triple combination therapy fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI 100/62.5/25 mcg) for patients with chronic obstructive pulmonary disease (COPD).
This follows the announcement of the submission of a new drug application for FF/UMEC/VI in the US in November 2016. The closed triple combination therapy comprises three medicines: fluticasone furoate, an inhaled corticosteroid (ICS), umeclidinium, a long-acting muscarinic antagonist (LAMA) and vilanterol, a long-acting beta2-adrenergic agonist (LABA), delivered once-daily in GSK’s Ellipta dry powder inhaler.
At 2:28pm: (LON:GSK) GlaxoSmithKline PLC share price was -8p at 1460.5p
Story provided by StockMarketWire.com
GSK confirms Japan approval for Relvar Ellipta
GlaxoSmithKline and Innoviva, have announced that the Japanese Ministry of Health, Labour and Welfare has approved Relvar Ellipta (fluticasone furoate / vilanterol 100/25 mcg) for the relief of various symptoms with chronic obstructive pulmonary disease (chronic bronchitis, pulmonary emphysema) (in the case where concurrent use of inhaled corticosteroid and long-acting inhaled beta2 agonist is required).
Relvar is a combination of the inhaled corticosteroid (ICS), fluticasone furoate ‘FF’, and the long-acting beta2 agonist (LABA), vilanterol ‘VI’.
The approved dose of FF/VI in chronic obstructive pulmonary disease (COPD) is 100/25 mcg administered once-daily using the Ellipta dry powder inhaler (DPI). Relvar Ellipta has been approved in Japan for the treatment of asthma since 2013 in two strengths – 100/25 mcg and 200/25 mcg.
Story provided by StockMarketWire.com
GSK confirms submission for shingles vaccine
GlaxoSmithKline has announced the regulatory submission of a Marketing Authorisation Application to the European Medicines Agency seeking approval for its candidate shingles vaccine, Shingrix, for the prevention of herpes zoster (shingles) in people aged 50 years or over. The candidate vaccine is a non-live, recombinant vaccine to help prevent shingles and its complications.
The phase III clinical trial programme showed that by reducing the incidence of shingles, the candidate vaccine also reduced the overall incidence of postherpetic neuralgia (PHN), a form of chronic pain associated with shingles.
Regulatory approval is being sought for the vaccine to be given intramuscularly in two doses, with a two-to-six month interval between doses.
The regulatory submission for the candidate vaccine is based on a comprehensive phase III clinical trial programme evaluating its efficacy, safety and immunogenicity in more than 37,000 people.
This includes the ZOE-50 and ZOE-70 studies published in the New England Journal of Medicine in April 2015 and September 2016, respectively.1,2
GSK senior vice-president and head of vaccines R&D, Dr Emmanuel Hanon, said: “Shingles is a common but serious condition that results from the reactivation of the virus that causes chicken pox and can cause lasting pain and other complications.
“The probability of developing shingles increases with age and it is estimated that up to one in every three people will develop shingles during their life. GSK’s shingles candidate vaccine has consistently shown high efficacy in older people in its phase III development programme. Today’s file submission puts us a step closer to making this vaccine available to help protect more people from shingles and the complications associated with it.”
At 1:53pm: (LON:GSK) GlaxoSmithKline PLC share price was +18.75p at 1541.75p
Story provided by StockMarketWire.com
GSK’s mepolizumab meets endpoints
GlaxoSmithKline says both co-primary endpoints and all secondary endpoints were met in a pivotal phase III study investigating the efficacy and safety of mepolizumab, an IL-5 antagonist, in patients with relapsing and refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA), a rare disease characterised by widespread inflammation in the walls of small blood vessels (vasculitis).
A key goal of treatment for EGPA is to induce and maintain remission while reducing the use of corticosteroids and other immunosuppressive therapies.
The co-primary endpoints for this 52-week study assessed the total duration of remission and the proportion of patients that achieved sustained remission following treatment with mepolizumab compared to treatment with placebo, both on top of standard of care.
Remission for these two endpoints was defined by a Birmingham Vasculitis Activity Score (BVAS), a scoring system to assess disease activity, of 0 and corticosteroid dose <4mg/day prednisolone/prednisone.
The study also included six secondary endpoints investigating relapse, remission and corticosteroid use, all considered clinically relevant for patients with EGPA. Patients demonstrated statistically significant differences, in favour of mepolizumab, for all secondary endpoints compared to placebo.
At 8:06am: (LON:GSK) GlaxoSmithKline PLC share price was +10.5p at 1514p
Story provided by StockMarketWire.com
